CA
NZ
UK
AU
IND
US
…
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
OmniAb Inc. provides antibody discovery platforms and related services to biopharma partners for therapeutic antibody identification. Long-term growth may be supported by rising global demand for biologic therapies and expanded partner collaborations that generate platform access and milestone revenue. Investors may find the company attractive because it appears positioned as a scalable technology provider that could benefit from outsourcing trends in drug discovery.
Material risks include reliance on partner-driven, milestone-based revenue, strong competition in discovery technologies, intellectual property exposure and ongoing financing needs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -66.29M | -71.41M | -64.36M | -26.06M | -34.35M |
| Net income | -64.78M | -62.03M | -50.62M | -22.33M | -27.04M |
| Selling general administrative | 29.21M | 30.74M | 33.31M | 24.90M | 16.95M |
| Selling and marketing expenses | - | - | 5.94M | - | - |
| Gross profit | -3.39M | 26.39M | 34.16M | 59.08M | 34.75M |
| Reconciled depreciation | 21.75M | 23.58M | 19.38M | 13.05M | 16.25M |
| Ebit | -66.29M | -71.41M | -64.36M | -26.65M | -35.61M |
| Ebitda | -44.54M | -47.83M | -44.87M | -13.01M | -18.09M |
| Depreciation and amortization | 21.75M | 23.58M | 19.50M | 13.64M | 17.52M |
| Operating income | -71.52M | -74.50M | -69.42M | -26.65M | -35.61M |
| Other operating expenses | 90.18M | 100.89M | 103.58M | 85.72M | 70.36M |
| Interest expense | - | - | - | 0.59M | 0.01M |
| Tax provision | -1.51M | -9.38M | -4.95M | -3.73M | -7.31M |
| Interest income | 2.66M | 3.11M | 4.46M | 0.59M | - |
| Net interest income | 2.66M | 3.11M | 4.46M | 0.59M | -0.01M |
| Income tax expense | -1.51M | -9.38M | -13.74M | -3.73M | -7.31M |
| Total revenue | 18.67M | 26.39M | 34.16M | 59.08M | 34.75M |
| Total operating expenses | 68.13M | 100.89M | 103.58M | 85.72M | 70.36M |
| Cost of revenue | 22.06M | 19.68M | 19.50M | - | - |
| Total other income expense net | 5.22M | 3.09M | 5.06M | 0.59M | 1.26M |
| Net income from continuing ops | -64.78M | -62.03M | -29.75M | -22.33M | -27.04M |
| Net income applicable to common shares | - | - | - | -22.33M | -27.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 300.91M | 325.56M | 401.99M | 421.21M | 304.46M |
| Intangible assets | 125.15M | 138.06M | 155.47M | 167.24M | 176.32M |
| Other current assets | 3.93M | 3.43M | 4.07M | 6.39M | 1.41M |
| Total liab | 33.89M | 37.94M | 87.40M | 79.84M | 70.16M |
| Total stockholder equity | 267.03M | 287.62M | 314.58M | 341.37M | 234.31M |
| Other current liab | 7.33M | 6.67M | 8.37M | 13.06M | 6.28M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 234.31M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | - |
| Retained earnings | -166.18M | -101.40M | -39.37M | 11.25M | - |
| Other liab | - | - | - | 29.80M | 36.31M |
| Good will | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
| Other assets | - | - | - | 3.58M | 1.50M |
| Cash | 25.52M | 27.60M | 16.36M | 33.39M | -13.85M |
| Total current liabilities | 16.25M | 15.09M | 23.12M | 26.02M | 20.58M |
| Current deferred revenue | 3.16M | 2.34M | 6.85M | 8.21M | 10.79M |
| Net debt | -5.19M | -4.43M | 9.20M | -7.59M | 27.70M |
| Short term debt | 3.88M | 3.78M | 3.49M | 1.78M | 0.58M |
| Short long term debt total | 20.33M | 23.16M | 25.56M | 25.80M | 13.85M |
| Other stockholder equity | 433.18M | 388.98M | 353.89M | 330.10M | 234.31M |
| Property plant equipment | - | - | - | 41.46M | 20.13M |
| Total current assets | 65.34M | 68.14M | 94.90M | 124.95M | 22.54M |
| Net tangible assets | - | - | - | 90.15M | -25.99M |
| Short term investments | 28.50M | 31.84M | 70.62M | 54.88M | - |
| Net receivables | 7.39M | 5.27M | 3.84M | 30.29M | 21.14M |
| Inventory | - | - | 0.00M | - | 13.85M |
| Accounts payable | 1.88M | 2.30M | 4.41M | 2.97M | 2.92M |
| Accumulated other comprehensive income | 0.01M | 0.03M | 0.05M | 0.01M | - |
| Non currrent assets other | 1.47M | 2.10M | 2.19M | -17.76M | 1.50M |
| Non current assets total | 235.57M | 257.42M | 307.08M | 296.26M | 281.92M |
| Capital lease obligations | 20.33M | 23.16M | 25.56M | 25.80M | 13.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 4.03M | 37.88M | -83.31M | -73.31M | 1.26M |
| Change to liabilities | - | - | - | 5.58M | -5.20M |
| Total cashflows from investing activities | 6.47M | 37.88M | -18.38M | -73.31M | -4.03M |
| Total cash from financing activities | 27.91M | 13.02M | -0.89M | 110.74M | 9.70M |
| Change to operating activities | - | - | - | -3.67M | -2.15M |
| Net income | -64.78M | -62.03M | -50.62M | -22.33M | -27.04M |
| Change in cash | -2.07M | 11.24M | -16.92M | 33.84M | 9.70M |
| Begin period cash flow | 28.16M | 16.92M | 33.84M | 0.00M | 0.00M |
| End period cash flow | 26.08M | 28.16M | 16.92M | 33.84M | 0.00M |
| Total cash from operating activities | -36.45M | -39.66M | 2.35M | -3.59M | -5.67M |
| Issuance of capital stock | 28.20M | 11.37M | 97.67M | 96.68M | - |
| Depreciation | 21.75M | 23.58M | 19.50M | 18.25M | 16.25M |
| Other cashflows from investing activities | 3.00M | -0.40M | -4.44M | -1.44M | -1.22M |
| Change to account receivables | 0.19M | -0.62M | 26.90M | -12.74M | 6.02M |
| Sale purchase of stock | - | - | -1.32M | - | - |
| Other cashflows from financing activities | -0.45M | 1.65M | -0.89M | 14.06M | 9.70M |
| Change to netincome | - | - | - | 11.33M | 7.75M |
| Capital expenditures | 0.56M | 1.88M | 1.64M | 17.17M | 4.07M |
| Change in working capital | -4.95M | -10.17M | 24.87M | -10.83M | -2.63M |
| Stock based compensation | 15.82M | 21.50M | 24.82M | 18.32M | 15.06M |
| Other non cash items | -2.77M | -3.50M | -3.68M | -0.57M | 0.01M |
| Free cash flow | -37.02M | -41.54M | 0.70M | -20.75M | -9.74M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OABI OmniAb Inc. |
-0.02 0.39% |
5.09 | - | - | 16.45 | 2.50 | 16.06 | -10.62 |
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew W. Foehr | Pres, CEO & Director | 1973 |
| Mr. Charles S. Berkman J.D. | Chief Legal Officer & Sec. | 1969 |
| Mr. Kurt A. Gustafson | Exec. VP of Fin. & CFO | 1968 |
| Dr. Bill Harriman Ph.D. | Sr. VP of Antibody Discovery | NA |
| Ms. Marie-Cecile van de Lavoir D.V.M., Ph.D. | Sr. VP of Technical Operations & Genetics | NA |
| Dr. Christel Iffland Ph.D. | Sr. VP of Antibody Technologies | NA |
| Dr. Douglas S. Krafte Ph.D. | Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head | 1958 |
| Ms. Donna Ventura CPA | Sr. VP of Corp. Controller | NA |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery | NA |
| Mr. Matthew W. Foehr | President, CEO & Director | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.09%
Communication Services
+0.21%
Consumer Cyclical
+1.14%
Consumer Defensive
+0.88%
Energy
-2.61%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.35%
Real Estate
+0.57%
Technology
-1.17%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...